I'm LongbridgeAI, I can summarize articles.AYTU BIOPHARMA reported FY2026 net revenue of $57.57M, a 13.3% decline from the prior year, with a net loss of ($14.25M) and diluted EPS of ($1.16). The company launched EXXUA (gepirone), generating $6.6M in initial sales, while divesting its Consumer Health business and winding down non-core programs. Management shifted resources to EXXUA commercialization, though it faces potential generic challenges to Adzenys.
AYTU BIOPHARMA, INC reported fiscal 2026 net revenue of $57.57M, down 13.3% from $66.38M a year earlier, and a net loss of ($14.25M) with diluted EPS of ($1.16) — results disclosed in its 10-K for the year ended 2026.
Financial Highlights
| Metric | Current year | Prior year | YoY change |
| Revenue¹ | $57.57M | $66.38M | (13.3%) |
| Net income² | ($14.25M) | ($13.56M) | (5.1%) |
| Diluted EPS³ | ($1.16) | ($2.16) | 46.3% |
¹ Reported as “Net revenue”. ² Reported as “Net loss”. ³ Reported as “Diluted income per share”.
Business Highlights
- Launched EXXUA (gepirone) in FY2026, generating $6.6M in initial sales and representing the company’s strategic shift toward prescription CNS products.
- Net revenue decline was partially offset by EXXUA’s launch as management redirected resources from pediatric and legacy ADHD products to EXXUA commercialization.
- Completed divestiture of the Consumer Health business, wound down non-core clinical programs, and transitioned Adzenys/Cotempla manufacturing to a U.S. contract manufacturer.
- Maintained product availability with no reported EXXUA or ADHD stock outages; faces potential generic challenge to Adzenys through Paragraph IV litigation.
Original SEC Filing: AYTU BIOPHARMA, INC [ AYTU ] - 10-K - Sep. 22, 2026